Article
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
The New England journal of medicine - 22 May 2014
Zeuzem Stefan, Dusheiko Geoffrey M, Salupere Riina, Mangia Alessandra, Flisiak Robert, Hyland Robert H, Illeperuma Ari, Svarovskaia Evguenia, Brainard Diana M, Symonds William T, Subramanian G Mani, McHutchison John G, Weiland Ola, Reesink Hendrik W, Ferenci Peter, Hézode Christophe, Esteban Rafael
Abstract excerpt
BACKGROUND: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection. METHODS: We conducted a study involving patients with HCV genotype 2 or 3 infection, some of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.